Trial Profile
A Retrospective, Observational study to evaluate the safety and effcacy of Radium-223-chloride in patients with metastatic castration-resistant prostate cancer (CRPC) and skeletal metastasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 08 May 2018 New trial record
- 01 Apr 2018 Results published in the Tumori